Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Thalidomide for prostate cancer: is there progress?

Nature Reviews Urology volume 6, pages 248–250 (2009)Cite this article

Upon its 'reinvention', thalidomide was quickly applied to 'microenvironment-dependent' diseases such as multiple myeloma, yet its role in the solid tumor spectrum has not been validated. A report into recurrent prostate cancer by Figg et al.1 shows that thalidomide can reduce time to PSA progression in patients treated with androgen deprivation therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Figg, W. D. et al. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J. Urol. 181, 1104–1113 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Kumar, S. & Anderson, K. C. Drug insight: thalidomide as a treatment for multiple myeloma. Nat. Clin. Pract. Oncol. 2, 262–270 (2005).

    Article  CAS  PubMed  Google Scholar 

  3. Figg, W. D. et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 7, 1888–1893 (2001).

    CAS  PubMed  Google Scholar 

  4. Dahut, W. L. et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. 22, 2532–2539 (2004).

    Article  CAS  PubMed  Google Scholar 

  5. Efstathiou, E. et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin. Cancer Res. 13, 1224–1231 (2007).

    Article  CAS  PubMed  Google Scholar 

  6. Garcia, J. A. et al. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin. Cancer Res. 14, 3052–3059 (2008).

    Article  CAS  PubMed  Google Scholar 

  7. Mao, S. et al. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 67, 1677–1685 (2007).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Eleni Efstathiou & Christopher J. Logothetis

Authors
  1. Eleni Efstathiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Logothetis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher J. Logothetis.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Efstathiou, E., Logothetis, C. Thalidomide for prostate cancer: is there progress?. Nat Rev Urol 6, 248–250 (2009). https://doi.org/10.1038/nrurol.2009.68

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2009.68

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing